Analysts Set Bausch Health Cos Inc. (NYSE:BHC) PT at $8.33

Shares of Bausch Health Cos Inc. (NYSE:BHC) have received a consensus rating of “Reduce” from the five ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $8.3333.

Several analysts recently weighed in on BHC shares. Truist Financial boosted their price objective on shares of Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a research note on Wednesday, January 7th. Raymond James Financial reaffirmed a “market perform” rating on shares of Bausch Health Cos in a research report on Monday, January 26th. Weiss Ratings downgraded Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a report on Thursday, February 19th. Wall Street Zen lowered Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 15th. Finally, Barclays decreased their price target on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 25th.

Institutional Trading of Bausch Health Cos

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Paulson & CO. Inc. lifted its holdings in Bausch Health Cos by 24.0% in the second quarter. Paulson & CO. Inc. now owns 32,791,702 shares of the company’s stock valued at $218,393,000 after buying an additional 6,352,667 shares during the period. Vanguard Group Inc. boosted its position in Bausch Health Cos by 4.0% during the third quarter. Vanguard Group Inc. now owns 12,241,072 shares of the company’s stock valued at $78,808,000 after acquiring an additional 470,968 shares during the last quarter. Goldentree Asset Management LP grew its holdings in Bausch Health Cos by 1.7% during the 3rd quarter. Goldentree Asset Management LP now owns 34,833,431 shares of the company’s stock worth $224,409,000 after acquiring an additional 578,542 shares during the period. Maple Rock Capital Partners Inc. raised its position in shares of Bausch Health Cos by 14.9% in the 2nd quarter. Maple Rock Capital Partners Inc. now owns 7,808,487 shares of the company’s stock worth $52,005,000 after acquiring an additional 1,010,987 shares in the last quarter. Finally, Private Management Group Inc. raised its position in shares of Bausch Health Cos by 13.6% in the 3rd quarter. Private Management Group Inc. now owns 1,621,725 shares of the company’s stock worth $10,460,000 after acquiring an additional 194,158 shares in the last quarter. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Cos Stock Performance

Shares of BHC stock opened at $5.37 on Friday. The business’s 50-day moving average price is $5.60 and its 200-day moving average price is $6.33. Bausch Health Cos has a 12 month low of $4.25 and a 12 month high of $8.69. The firm has a market capitalization of $2.00 billion, a price-to-earnings ratio of 12.77 and a beta of 0.40. The company has a current ratio of 1.47, a quick ratio of 1.08 and a debt-to-equity ratio of 54.68.

Bausch Health Cos (NYSE:BHC) last released its quarterly earnings data on Wednesday, February 18th. The company reported $1.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.21 by ($0.13). Bausch Health Cos had a net margin of 1.53% and a return on equity of 875.00%. The firm had revenue of $2.78 billion during the quarter, compared to analyst estimates of $2.71 billion. Equities research analysts forecast that Bausch Health Cos will post 4.41 EPS for the current year.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.